Differential impact of rheumatoid factor on biologic persistence in rheumatoid arthritis: non-TNF inhibitors versus certolizumab pegol

OBJECTIVES: High rheumatoid factor (RF) titres may affect Fc-containing biologic persistence in rheumatoid arthritis (RA), but evidence beyond TNF inhibitors is limited. We assessed whether baseline RF > 203 IU/mL was associated with persistence and first-year disease activity in patients with RA receiving certolizumab pegol (CZP), rituximab (RTX), tocilizumab (TCZ), or abatacept (ABT). METHODS: A multicentre retrospective longitudinal study of adults with RA initiating CZP, RTX, TCZ or ABT within the first three lines of b/tsDMARD therapy (2001-2024). After excluding repeated courses, 541 patients remained; 436 had eligible baseline RF and formed the RF-stratified sample. Patients were stratified as RF ≤ 203 or > 203 IU/mL. Persistence was analysed with Kaplan-Meier and competing-risk models for secondary inefficacy; disease activity was assessed at 6 and 12 months. RESULTS: Among 541 patients, 105 received CZP, 167 RTX, 145 TCZ, and 124 ABT. In RF-stratified analyses, 135/436 (31%) had RF > 203 IU/mL. Shorter persistence in high-RF patients was observed only with TCZ (median 1.18 versus 2.03 years; p = 0.011). RF > 203 IU/mL independently predicted TCZ discontinuation due to secondary inefficacy (HR 4.92, 95% CI 1.66-14.58; p = 0.004), but not CZP or RTX discontinuation. In ABT, few events among high-RF patients precluded reliable adjusted estimation. RF was not consistently associated with short-term clinical response. CONCLUSION: High baseline RF identified TCZ-treated patients at increased risk of shorter persistence and secondary inefficacy, whereas no similar association was observed for CZP or RTX. ABT results remain inconclusive because of limited events. These findings suggest agent-specific clinical relevance of RF.

Authors

Institutions

Publication Details

Journal
Rheumatology
Published
2026-11-20
DOI
https://doi.org/10.1093/rheumatology/keag561
Primary Topic
Rheumatoid Arthritis Research and Therapies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Differential impact of rheumatoid factor on biologic persistence in rheumatoid arthritis: non-TNF inhibitors versus certolizumab pegol

Fernando Corvillo, Clementina López‐Medina, Rebeca Pérez de Diego, Marta Novella-Navarro et al.
Rheumatology
Rheumatoid Arthritis Research and Therapies
article

Differential impact of rheumatoid factor on biologic persistence in rheumatoid arthritis: non-TNF inhibitors versus certolizumab pegol

Fernando Corvillo, Clementina López‐Medina, Rebeca Pérez de Diego, Marta Novella-Navarro, Ana Martínez‐Feito, Carolina Tornero, Carmen Cámara Hijón, Jaime Calvo‐Alén, Fernando Manuel Pimentel-Santos, Eugenio de Miguel, Chary López-Pedrera, Gema Bonilla, J. F. Garcia Llorente, Mariana Díaz‐Almirón, Francisco Javier de Toro Santos, Francisco Cepas, Chamaida Plasencia, Manuel Juárez-García, Vicent Ribas-Macías, Lara Dávila-Seijo, Sara Salas-Santamaría, Marta Flores de Francisco, Odelaysi León
article en

Abstract

OBJECTIVES: High rheumatoid factor (RF) titres may affect Fc-containing biologic persistence in rheumatoid arthritis (RA), but evidence beyond TNF inhibitors is limited. We assessed whether baseline RF > 203 IU/mL was associated with persistence and first-year disease activity in patients with RA receiving certolizumab pegol (CZP), rituximab (RTX), tocilizumab (TCZ), or abatacept (ABT). METHODS: A multicentre retrospective longitudinal study of adults with RA initiating CZP, RTX, TCZ or ABT within the first three lines of b/tsDMARD therapy (2001-2024). After excluding repeated courses, 541 patients remained; 436 had eligible baseline RF and formed the RF-stratified sample. Patients were stratified as RF ≤ 203 or > 203 IU/mL. Persistence was analysed with Kaplan-Meier and competing-risk models for secondary inefficacy; disease activity was assessed at 6 and 12 months. RESULTS: Among 541 patients, 105 received CZP, 167 RTX, 145 TCZ, and 124 ABT. In RF-stratified analyses, 135/436 (31%) had RF > 203 IU/mL. Shorter persistence in high-RF patients was observed only with TCZ (median 1.18 versus 2.03 years; p = 0.011). RF > 203 IU/mL independently predicted TCZ discontinuation due to secondary inefficacy (HR 4.92, 95% CI 1.66-14.58; p = 0.004), but not CZP or RTX discontinuation. In ABT, few events among high-RF patients precluded reliable adjusted estimation. RF was not consistently associated with short-term clinical response. CONCLUSION: High baseline RF identified TCZ-treated patients at increased risk of shorter persistence and secondary inefficacy, whereas no similar association was observed for CZP or RTX. ABT results remain inconclusive because of limited events. These findings suggest agent-specific clinical relevance of RF.

Rheumatology
Universidade da Coruña (ES), Hospital Universitario La Paz (ES), Hospital de Basurto (ES), Hospital La Paz Institute for Health Research (ES), Hospital de Egas Moniz (PT), Hospital Universitario Araba (ES), Hospital Universitario Reina Sofía (ES), Centro Hospitalar de Lisboa Ocidental (PT)
Rheumatoid Arthritis Research and Therapies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon